Update on therapy of atopic dermatitis

Journal of Allergy and Clinical Immunology

Volumn 104, Issue 3 SUPPL., 1999, Pages

  Hanifin, Jon M ^a   Tofte, Susan J ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Atopic dermatitis; Bathing moisturizing; Trigger factors

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; DERMATOLOGICAL AGENT; GAMMA INTERFERON; MACROLIDE; PHOSPHODIESTERASE INHIBITOR; TACROLIMUS;

ANAMNESIS; ATOPIC DERMATITIS; BATH; DRUG INDUCED DISEASE; HUMAN; PATIENT EDUCATION; PHYSICAL EXAMINATION; PRIORITY JOURNAL; REVIEW; SKIN CARE; TOPICAL DRUG ADMINISTRATION; TREATMENT PLANNING;

COMBINED MODALITY THERAPY; DERMATITIS, ATOPIC; HUMANS;

EID: 0032833699     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0091-6749(99)70054-0     Document Type: Article

References (15)

1. Hanifin JM. Atopic dermatitis. In: Middleton E, Reed CE, Ellis EF, Busse B, editors. Allergy: principles and practice. 4th ed. St Louis (MO): Mosby-Year Book, Inc; 1993. p. 1581-604.
2. Hanifin JM, Chan SC. Monocyte phosphodiesterase abnormalities and dysregulation of lymphocyte function in atopic dermatitis. J Invest Dermatol 1995;105(suppl):84S-8S.
3. Whitmore SE. Should atopic individuals be patch tested? Dermatol Clin 1994;12:491-9.
4. Hanifin JM. Pharmacophysiology of atopic dermatitis. Clin Rev Allergy 1986;4:43-65.
5. Hanifin JM. Do mast cells play a role in atopic dermatitis? In: Kaliner M, Metcalfe D, editors. The mast cell in health and disease. New York: Marcel Dekker, Inc; 1992. p. 639-51.
6. Sowden JM, Berth-Jones J, Ross JS, Motley RJ, Marks R, Finlay AY, et al. Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis. Lancet 1991;338:137-40.
7. Stevens SR, Hanifin JM, Hamilton T, Tofte SJ, Cooper KD. Long-term effectiveness and safety of recombinant human interferon-gamma therapy for atopic dermatitis despite unchanged serum IgE levels. Arch Dermatol 1998;134:799-804.
8. Hanifin JM, Chan SC, Cheng JB, Tofte SJ, Henderson WR Jr, Kirby DS, et al. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J Invest Dermatol 1996;107:51-6.
9. Christensen SB, Guider A, Forster CJ, Gleason JG, Bender PE, Karpinksi JM, et al. 1,4-Cyclohexanecarboxylates: potent and selective inhibitors of phosphodiesterase 4 for the treatment of asthma. J Med Chem 1998;41:821-35.
10. 4 cyclic adenosine monophosphate-specific phosphodiesterase family: intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions. Adv Pharmacol 1998;44:225-342.
11. Ruzicka T, Bieber T, Schöpf E, Rubins A, Dobozy A, Bos JD, et al (for the European Tacrolimus Multicenter Atopic Dermatitis Study Group). A short-term trial of tacrolimus ointment for atopic dermatitis. N Engl J Med 1997;337:816-21.
12. Boguniewicz M, Fiedler VC, Raimer S, Lawrence ID, Leung DYM, Hanifin JM. A randomized vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. J Allergy Clin Immunol 1998;102:637-44.
13. Van Leent EJM, Graber M, Thurston M, Wagenaar A, Spuls PI, Bos JD. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol. 1998;134:805-9.
14. Schultz-Larsen F, Diepgen T, Svensson A. The occurrence of atopic dermatitis in North Europe: an international questionnaire study. J Am Acad Dermatol 1996;34:760-4.
15. Lapidus CS, Schwarz DF, Honig PJ. Atopic dermatitis in children: Who cares? Who pays? J Am Acad Dermatol 1993;28:699-703.